NCT04805255: A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 84 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must be eligible for hypofractionated stereotactic radiotherapy (HF-SRT)
Exclusions: Patients with more than 3 metastatic lesions; Patients with metastasis involving the brain stem; Patients with leptomeningeal disease; Patients with prior radiotherapy including stereotactic radiosurgery delivered to brain/head region for any reasons

Comments are closed.

Up ↑